

GLADEL - Authorship and Participation

Version 5.0 (May 10, 2024)

1) About Authorship and Participation

1.1. GLADEL Cohorts

- The authors of the first publication of the GLADEL cohort (1997), GLADEL 2.0 (2019), and future cohorts will be led by the principal investigator and collaborator of the project submitted to Pro&Pub. Similarly, the corresponding author (last on the list of authors) will be selected by the lead authors of the project. Following this, the principal investigators of the centers, or those designated by them, will be listed, up to the maximum limit authorized by the selected journal for publication.
- The order of authorship will be related to the number of patients enrolled in the cohort, as well as the quality of the information evaluated by the Data Control Committee.
- All other center investigators will be included in an annex at the end of the publication.

1.2. Additional Projects

- **Database**
Centers are encouraged to submit "Additional Projects," using the databases of the "original GLADEL" and "GLADEL 2.0" cohorts, as well as the educational databases of "Let's Talk about Lupus," "Falandó do Lupus," "Is it Lupus?" or others to be developed in the future.
- **Presentation format**
All additional projects must be submitted to the GLADEL Scientific Committee using the specifically designed format (see: GLADEL - Standard Operating Procedures – SOP) (Version 5.0, May 10, 2024).
- **Scientific Committee**
The Scientific Committee will consist of 3 members whose functions include: a) reviewing and potentially approving projects submitted to GLADEL; b) conducting quarterly follow-ups on accepted projects, with reporting to the Executive Council; c) reviewing final manuscripts prior to publication; d) suggesting indexed journals for publication.
- **Maximum Project Timeline**
The maximum time for the development of an additional project, from the approval of the project by the Scientific Committee to its presentation at a national/international congress, is 12 months, and for submission to an indexed journal, it is 18 months.
- **Authors**
Investigators involved in an additional project accepted by the Scientific Committee will be the authors of the presentations and/or publications resulting from that project.

The order of authors in the presentations and/or publications must be agreed upon in advance by each working group. If the contribution of more than one author is considered equal, shared authorship for the first author can be decided.

Active participation in GLADEL and compliance with all requirements for participation in the research project, manuscript writing and/or review until publication, are necessary for authorship.

- **Responsibility of Lead Authors**

The lead authors of an additional project are responsible for fulfilling all stages of the research/publication, adhering to the established work schedule, providing progress reports to the Scientific Committee, and publishing the study in a timely manner. This includes submitting the manuscript to all co-authors for review until approval, uploading the manuscript to the selected indexed journal platform, and addressing reviewer comments until final approval for publication.

- **Number of Authors**

It is well known that scientific journals currently limit the total number of authors for each publication. Therefore, GLADEL encourages additional projects to provide opportunities for its members to conduct studies using the scientific and educational databases of GLADEL cohorts and disseminate them through publications in indexed journals.

- **Author Annex**

All centers and/or investigators that have only contributed data or samples for such project/s will be listed in an Annex as part of the "**GLADEL Consortium.**"

- **Center Rating**

GLADEL will establish a score for the centers based on the number of patients and the quality of the information in each database. In all additional works submitted for publication, the total number of accepted authors will be filled after the lead authors of the project, by those principal or associate investigators in the best position in the rating list, until the quota of the scientific journal to which the manuscript will be submitted is complete. In subsequent publications, those in second place will be included, and so on, until all GLADEL centers are included. The cycle restarts with the next publication. GLADEL establecerá un puntaje para los centros.

- **Authorship Conflict**

In cases of authorship conflict, the GLADEL Scientific Committee will act as a mediator and arbiter between the parties, with its decision being final and unappealable.

Members of the Scientific Committee involved as authors will be excluded from voting. They will be replaced and selected by lot from the Scientific Committee members and/or GLADEL researchers.

- **ARTHROS Program**

The ARTHROS program (version used) must be included in the "Materials and Methods" of all presentations and/or publications originating from the GLADEL database.

- **PANLAR**

As a Lupus Study Group of PANLAR, GLADEL is committed to mentioning PANLAR in the acknowledgments of all its publications.

1.3. Collaborative Projects

- GLADEL's international recognition has allowed its cohorts (GLADEL and GLADEL 2.0) to be invited to participate in multicenter, multinational collaborative projects.
- In these cases, the number of GLADEL authors will be subject to the magnitude of the collaborative project and the number of authors allowed for each publication.
- GLADEL will continue to include the maximum possible number of authors in each publication and rotate authorship to maintain balance in participation. Whenever possible, an annex of collaborators will be included in each publication, listing all participants.

1.4. Projects Subsidized by the Pharmaceutical Industry

- In cases where a project is subsidized by the pharmaceutical industry or another external organization, a limited number of authors from that company or organization will be allowed, subject to agreement between the parties.
- In all cases, the sponsor will be included in the acknowledgments section, mentioning the type of subsidy received (unrestricted grant, investigator-initiated project, others).